What is the appropriate progesterone dosing regimen for hormone replacement therapy?

Progesterone Dosing for Hormone Replacement Therapy

For women with an intact uterus receiving estrogen replacement, progesterone should be administered at 200 mg daily for 12-14 days per 28-day cycle (sequential regimen) or 100 mg daily continuously, with micronized progesterone (MP) as the preferred first-line progestogen. 1, 2

Sequential (Cyclic) Regimen Dosing

When withdrawal bleeding is acceptable, administer progestogen cyclically for endometrial protection:

Micronized Progesterone (First Choice):

• 200 mg orally or vaginally for 12-14 days every 28 days 1
• This is the preferred option due to lower cardiovascular and thromboembolism risk 1

Alternative Progestogens (Second Choice):

• Medroxyprogesterone acetate (MPA): 10 mg daily for 12-14 days per month 1, 2
• Dydrogesterone: 10 mg daily for 12-14 days per month 1
• Norethindrone acetate: 5 mg daily for 10-12 days per month 2

The sequential approach typically produces monthly withdrawal bleeding, which some patients find acceptable. The 12-14 day duration is critical—shorter durations provide inadequate endometrial protection 3, 2.

Continuous Combined Regimen Dosing

When amenorrhea is desired to avoid withdrawal bleeding:

Micronized Progesterone:

• 100 mg daily continuously 1, 4
• This lower dose effectively suppresses endometrial mitoses and induces amenorrhea in >90% of women 4

Alternative Continuous Progestogens:

• MPA: 2.5 mg daily 2
• Dydrogesterone: 5 mg daily 1
• Norethisterone: 1 mg daily minimum 1
• Levonorgestrel: 0.075 mg daily 2

Important caveat: Recent evidence suggests continuous progestogen exposure may increase breast cancer risk compared to sequential regimens 3, 2. However, continuous regimens achieve higher rates of amenorrhea, improving compliance.

Route of Administration Considerations

Oral administration is most common and well-studied 2, 5. The FDA-approved progesterone capsule demonstrated that 200 mg daily for 12 days per cycle reduced endometrial hyperplasia from 64% (estrogen alone) to 6% (estrogen plus progesterone) over 36 months 5.

Vaginal administration of micronized progesterone at the same doses (100-200 mg) achieves adequate endometrial protection with potentially fewer systemic side effects 1, 2. This route may be preferred when oral progestogens cause intolerable side effects.

Transdermal patches combining estradiol with progestogen (e.g., levonorgestrel 7-10 μg daily) are available in some countries and offer convenience 1.

Special Populations

Young women with premature ovarian insufficiency (including cancer survivors): The same dosing applies, but micronized progesterone is strongly preferred as first-line due to superior cardiovascular safety profile in this higher-risk population 1.

Women requiring contraception: Higher-dose combined oral contraceptives may be more appropriate than standard HRT 1.

Critical Monitoring Points

• Any abnormal bleeding during therapy requires immediate endometrial evaluation with ultrasound and biopsy 2
• Breakthrough bleeding is common in the first year of continuous combined therapy but should decrease over time 2
• The progestogen dose must be adequate for the estrogen dose administered—higher estrogen doses may require adjustment 1

Common Pitfalls to Avoid

1. Insufficient duration: Using progestogen for <10 days per month provides inadequate endometrial protection 3, 2
2. Omitting progestogen entirely: Unopposed estrogen increases endometrial cancer risk 2-6 fold 3
3. Using anti-androgenic progestins in women with sexual dysfunction: This can worsen hypoandrogenism 1
4. Ignoring patient preference: Poor compliance due to bleeding or side effects undermines therapy effectiveness 2

The evidence strongly supports micronized progesterone as first-line over synthetic progestins due to its more favorable metabolic, cardiovascular, and thrombotic profile 1, 6, though synthetic progestins remain acceptable alternatives when micronized progesterone is unavailable or not tolerated.